Vacciguard Novel Vaccines

Using novel peptide carriers VacciGuard's platform technology enables the generation of innovative vaccines both for prevention of infectious diseases and for the treatment of devastating diseases such as cancer.

VacciGuard's technology consists of proprietary peptide carriers, derived from the Heat Shock Protein 60 (HSP60). These carriers, when conjugated to a poor immunogenic antigen (e.g. bacteria capsule polysaccharide, viral peptide), have been shown to activate T cells to support the generation of long-lasting immune memory against the specific antigen, even in the absence of boosting and additional adjuvant.

The conjugated vaccine has been found to produce long-lasting IgG antibodies and to activate the Toll Like Receptor 4 (TLR4), elevating IL-12 and IFN-g cytokine levels.

HSP-60 is a powerful natural immunogen which is upregulated at sites of inflammation, stress and infection. The protein demonstrates remarkable conservation throughout evolution.

Proof- of- concept for five different pathogens has been demonstrated in relevant mouse models